Elily's Zepbound的减重结果比Novo Nordisk's Wegovy在一项新研究中 的减重结果要好。 Eli Lilly's Zepbound shows better weight loss results than Novo Nordisk's Wegovy in a new study.

Elily的新减肥药Zepbound 与Novo Nordisk的Wegovy 相比, Eli Lilly's new weight loss drug, Zepbound, has shown superior results compared to Novo Nordisk's Wegovy in a recent trial. 在751人参与的研究中,Zepbound在72周后平均导致体重减少20.2%(50.3磅),而Wegovy为13.7%(33.1磅)。 In the 751-participant study, Zepbound led to an average 20.2% weight loss (50.3 pounds) after 72 weeks, compared to 13.7% (33.1 pounds) for Wegovy. 这两种药物都模仿一种控制食欲和消化的荷尔蒙,但Zepbound也针对另外一种荷尔蒙,有可能提高其效力。 Both drugs mimic a hormone that controls appetite and digestion, but Zepbound also targets an additional hormone, potentially enhancing its effectiveness. 常见副作用包括胃肠问题。 Common side effects included gastrointestinal issues. 这些调查结果可能会影响今后的治疗偏好和保险范围。 These findings could influence future treatment preferences and insurance coverage.